Literature DB >> 29940039

Correction: Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

María Buti, María L Manzano, Rosa M Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M Zozaya, Miguel A Simón, Luis E Morano, José L Calleja, María Yébenes, Rafael Esteban.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0184550.].

Entities:  

Year:  2018        PMID： 29940039      PMCID： PMC6016912          DOI： 10.1371/journal.pone.0199926

Source DB:  PubMed          Journal:  PLoS One        ISSN： 1932-6203            Impact factor:   3.240


  1 in total

1.  Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.

Authors:  María Buti; María L Manzano; Rosa M Morillas; Montserrat García-Retortillo; Leticia Martín; Martín Prieto; María L Gutiérrez; Emilio Suárez; Mariano Gómez Rubio; Javier López; Pilar Castillo; Manuel Rodríguez; José M Zozaya; Miguel A Simón; Luis E Morano; José L Calleja; María Yébenes; Rafael Esteban
Journal:  PLoS One       Date:  2017-09-12       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.